Recent Developments

Arsanis and X4 Pharmaceuticals Agree to Merger

CAMBRIDGE, Mass. and WALTHAM, Mass. and VIENNA, Austria, Nov. 27, 2018 (GLOBE NEWSWIRE) — Arsanis, Inc. (Nasdaq: ASNS) and privately-held X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics designed to improve immune … Continue reading

Posted in Recent Development News: Q4 - 2018, Recent Developments | Comments Off

Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation

BALTIMORE, Oct. 31, 2018 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has submitted … Continue reading

Posted in Recent Development News: Q3 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics Begins U.S. IPO Effort

CNTX intends to raise $86.25 million in gross proceeds from an IPO of its common stock, not including customary underwriter options. No existing shareholders have indicated an interest to purchase shares of the IPO, although I would expect to see … Continue reading

Posted in Recent Development News: Q3 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma

Cambridge, MA – May 15, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals to Present Clinical Data from Phase 2 Study of X4P-001-RD in WHIM syndrome

Cambridge, MA – May 17, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001-RD, the company’s CXCR4 … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P001-IO and Inlyta®(axitinib) in Patients with Clear Cell Renal Cell Carcinoma

Cambridge, MA – May 16, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001-IO, the company’s CXCR4 … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma

Cambridge, MA – May 15, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 antagonists to improve immune cell trafficking to treat cancer and rare disease, today announced results from a pilot study of X4P-001-IO in combination … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

ContraFect Announces First Quarter 2018 Financial Results

YONKERS, N.Y. , May 10, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced results for the first quarter ended … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

Jeffrey Modell Foundation and X4 Pharmaceuticals to Sponsor First Genetic Screening Study for Patients with WHIM Syndrome

NEW YORK, N.Y. and CAMBRIDGE, Mass. April 24, 2018 – The Jeffrey Modell Foundation, a nonprofit organization for primary immunodeficiency diseases, and X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs, today announced that they are jointly … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

Centrexion Therapeutics Announces CNTX-4975 and CNTX-6970 Clinical Data Presentations at the 34th Annual American Academy of Pain Medicine Meeting

BOSTON, Mass., April 19, 2018 – Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced it will present Phase 1 safety and tolerability data of single ascending doses of CNTX-6970 … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity

CAMBRIDGE, Mass., April 16, 2018 – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare diseases, today highlighted data from a presentation at the 2018 American Association … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off

ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

YONKERS, N.Y., April 11, 2018 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the presentation of data on its lead … Continue reading

Posted in Recent Development News: Q2 - 2018, Recent Developments | Comments Off